Luminus Management LLC Sells 136,195 Shares of Lucid Diagnostics Inc. (NASDAQ:LUCD)

Luminus Management LLC cut its stake in Lucid Diagnostics Inc. (NASDAQ:LUCD) by 11.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,016,720 shares of the company’s stock after selling 136,195 shares during the period. Lucid Diagnostics makes up approximately 1.0% of Luminus Management LLC’s holdings, making the stock its 12th biggest position. Luminus Management LLC’s holdings in Lucid Diagnostics were worth $832,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. LPL Financial LLC boosted its holdings in Lucid Diagnostics by 29.1% in the 4th quarter. LPL Financial LLC now owns 53,391 shares of the company’s stock valued at $44,000 after purchasing an additional 12,035 shares during the period. Citadel Advisors LLC bought a new stake in Lucid Diagnostics in the fourth quarter valued at about $98,000. Lido Advisors LLC raised its position in Lucid Diagnostics by 40.0% in the fourth quarter. Lido Advisors LLC now owns 140,016 shares of the company’s stock worth $115,000 after purchasing an additional 40,000 shares in the last quarter. Geode Capital Management LLC raised its position in Lucid Diagnostics by 30.9% in the fourth quarter. Geode Capital Management LLC now owns 279,504 shares of the company’s stock worth $229,000 after purchasing an additional 65,964 shares in the last quarter. Finally, Sargent Investment Group LLC acquired a new position in Lucid Diagnostics in the fourth quarter worth about $442,000. 74.01% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the stock. Needham & Company LLC reissued a “buy” rating and issued a $3.00 price target on shares of Lucid Diagnostics in a research report on Friday, April 11th. Cantor Fitzgerald reissued an “overweight” rating and issued a $2.00 price target on shares of Lucid Diagnostics in a research report on Wednesday, March 26th. Ascendiant Capital Markets increased their price target on shares of Lucid Diagnostics from $7.00 to $7.50 and gave the stock a “buy” rating in a research report on Monday, April 21st. Finally, BTIG Research set a $2.00 price target on shares of Lucid Diagnostics in a research report on Tuesday, March 25th. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Lucid Diagnostics currently has an average rating of “Buy” and a consensus target price of $3.50.

Lucid Diagnostics Trading Down 5.0%

NASDAQ LUCD opened at $1.13 on Monday. The firm has a market cap of $119.08 million, a price-to-earnings ratio of -0.99 and a beta of 1.28. The company has a 50 day moving average of $1.36 and a 200-day moving average of $1.12. Lucid Diagnostics Inc. has a 1-year low of $0.68 and a 1-year high of $1.80.

Lucid Diagnostics Profile

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.